Oncotarget is a weekly peer-reviewed open access medical journal that started out covering research from all aspects of oncology. The journal was first established in 2010 and was published originally by Impact Journals. Ever since Oncotarget launched it has expanded its platform and has become one of the biggest sources of information for research done in the world of Oncology.
How Does this Benefit World of Medical Research?
One of the drawbacks in research, especially in the medical field, is the access to information researchers have daily. There is a pervading sense of competition when it comes to research in this field when there shouldn’t be. This causes a rift between researchers since each one is aiming for that ‘next big breakthrough’ to help combat the disease. While the latter is certainly a worthy cause, it also creates an unnecessary wall between researchers to share valuable information with each other that could help with a new breakthrough.
This is where Oncotarget steps in by being an open access medical journal researchers and oncologists can refer too. The goal of the medical access journal is to have an impact on the research done by the authors. They cover a variety of topics in oncology and have continued to expand their ranks by accepting papers on topics beyond just this area of research.
Other topics Oncotarget is looking to expand into include the following:
- Cell Biology
Read more: https://www.dovepress.com/oncotargets-and-therapy-journal
Their mission is to take these scientific results and make them available as widely and rapidly as possible. Ensuring researchers across the globe have access to this research will help to have a greater impact on the information going into these topics. Bridging that gap between researchers so they can share information freely with peers helps to nurture the progress of science. Ultimately, through their medical journal Oncotarget helps to one day see life without disease for people across the globe. Oncotarget is published by Impact Journals.
Dr. Mikhail Blagosklonny is a world’s prominent oncologist and a researcher. He is experienced in cancer research on Impactjournals.com and works as a professor at the New York-based Roswell Park Cancer Institute. His brilliant works are recognized within and outside the United States.
Academics and professional expertise
Dr. Blagosklonny became a senior researcher and tutor at Roswell Park Cancer Institute New York in 2009. His appointment came after the Institute reviewed his extensive work experience gained from working with both colleges and other research institutes. He has an M.D in internal medicine and Ph.D. in cardiology and experimental medicine.
Upon completion of his higher studies, Dr. Blagosklonny was called upon to serve as an associate professor at New York Medical College. He taught all medical students at the college. In 2002, he was appointed as the senior scientist at Ordway Research Institute headquartered in Albany, New York. This position allowed Dr. Blagosklonny to focus on his life extension research on impactjournals.com.
Dr. Blagosklonny’s interests and research hypothesis
Dr. Blagosklonny research interests are remarkable; they include cancer, aging, targeted cancer therapies that protect normal cells from cancerous ones, and anti-aging drugs. He has made big strides in research world by formulating a hypothesis in the significance of TOR Signaling in aging and cancer. Dr. Mikhail Blagosklonny proposed that Rapamycin, a popular cancer drug, might be used to extend life. He has held this concept for years, and he hopes to prove it in the future.
Dr. Blagosklonny is the founder and chief editor of Oncotarget. Oncotarget is a peer-reviewed medical journal covering all areas of aging and oncology. Dr. Blagosklonny co-founded Oncotarget together with Andrei Gudkov in 2010. This journal is the leading open-access oncology journal in the United States. Additionally, he edits other journals such as Cancer Biology & Therapy. Dr. Blagosklonny also serves on the editorial board of Cell Death & Differentiation. He has authored over 270 papers with over 250,000 citations.